Target intelligence / Profile preview

Immunoglobulin E specific for Sin a 1 (Sin a 1-sIgE)

Target
Sin a 1-sIgE
Molecular classification
Antibody, Immunoglobulin, Glycoprotein, Receptor, Other
01

Overview

IgE antibodies specific for Sin a 1 are the primary immunological drivers of yellow mustard (Sinapis alba) allergy. Sin a 1 is a 2S albumin seed storage protein and is recognized as the major allergen in mustard due to its high prevalence of sensitization among mustard-allergic individuals (Palomares et al., 2005). These specific IgE antibodies circulate in the blood and bind to the high-affinity FcεRI receptors on the surface of mast cells and basophils. Upon subsequent exposure to mustard, the Sin a 1 protein cross-links these receptor-bound IgE molecules, triggering the immediate release of inflammatory mediators like histamine, which causes symptoms ranging from mild skin reactions to systemic anaphylaxis (Sirvent et al., 2012). While there are no therapies that exclusively target Sin a 1-specific IgE, the monoclonal antibody Omalizumab acts as a general IgE blocker by binding to the Fc region of IgE, thereby preventing the allergic cascade (Gould & Sutton, 2008). Measurement of Sin a 1-specific IgE levels in serum is a standard diagnostic tool used to confirm mustard allergy and assess the risk of severe reactions (Monsalve et al., 2001).

Other names
Anti-Sin a 1 IgESin a 1-specific IgEYellow mustard allergen-specific IgESin a1-specific IgESinapis alba allergen 1-specific IgE
02

Mechanism of action

Neutralization of circulating IgE antibodies and prevention of their binding to high-affinity FcεRI receptors on mast cells and basophils.

03

Biological functions

Immune responseType I hypersensitivityMast cell degranulationBasophil activation
04

Disease associations

InflammationFood allergyAnaphylaxisOther
05

Safety considerations

Risk of anaphylaxis during diagnostic testing or allergen-specific immunotherapyPotential for cross-reactivity with other 2S albumin allergens from nuts and seedsTherapeutic challenges in patients with extremely high total IgE titers
06

Interacting drugs

Omalizumab

2 more in the full profile.

07

Biomarkers

Serum Sin a 1-specific IgE levelsBasophil activation test (BAT)Skin prick test reactivity

Beyond the preview

Go deeper on Immunoglobulin E specific for Sin a 1 (Sin a 1-sIgE).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immunoglobulin E specific for Sin a 1 (Sin a 1-sIgE).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call